Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections

Journal of the Formosan Medical Association

Volumn 104, Issue 11, 2005, Pages 783-791

  Liu, Chun Jen ^a   Liou, Jyh Ming ^a   Chen, Ding Shinn ^a   Chen, Pei Jer ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Antiviral agents; Hepacivirus; Hepatitis B virus; Review; Treatment outcome

Indexed keywords

ANTIVIRUS AGENT; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; RIBAVIRIN; VIRUS RNA;

CLINICAL FEATURE; DISEASE ASSOCIATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; MIXED INFECTION; PREVALENCE; REVIEW; TREATMENT OUTCOME; BLOOD;

ANTIVIRAL AGENTS; HEPATITIS B; HEPATITIS C; HUMANS; RNA, VIRAL;

EID: 33645295816     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Chen DS, Kuo GC, Sung JL, et al: Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis 1990;162:817-22.
2. Gaeta GB, Stornaiuolo G, Precone DF, et al: Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J Hepatol 2003;39:1036-41.
3. Yang HI, Lu SN, Liaw YF, et al: Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-74.
4. Sun CA, Wu DM, Lin CC, et al: Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol 2003;157:674-82.
5. Liaw YF, Chen YC, Sheen IS, et al: Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 2004;126:1024-9.
6. Strader DB, Wright T, Thomas DL, et al: American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71.
7. Liu CJ, Chen PJ, Chen DS: A forgotten population with chronic hepatitis C infection: subjects coinfected with hepatitis B virus. Hepatology 2004;40:266.
8. Sagnelli E, Coppola N, Messina V, et al: HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology 2002;36:1285-91.
9. Francois M, Roingeard P, Dubois F, et al: Lower serum hepatitis C virus RNA titers in patients with concurrent chronic hepatitis B virus infection. J Infect Dis 1994;169:1411-2.
10. Mathurin P, Thibault V, Kadidja K, et al: Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections. J Viral Hepat 2000;7:15-22.
11. Dienes HP, Purcell RH, Popper H, et al: The significance of infections with two types of viral hepatitis demonstrated by histologic features in chimpanzees. J Hepatol 1990;10:77-84.
12. Liu CJ, Chen PJ, Lai MY, et al: Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 2003;37:568-76.
13. Marrone A, Zampino R, D'Onofrio M, et al: Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection. J Hepatol 2004;41:1064-5.
14. Weltman MD, Brotodihardjo A, Crewe EB, et al: Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat 1995;2:39-45.
15. Liaw YF, Chien RN, Lin SM, et al: Response of patients with dual hepatitis B virus and C virus infection to interferon therapy. J Interferon Cytokine Res 1997;17:449-52.
16. Villa E, Grottola A, Buttafoco P, et al: High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. Am J Gastroenterol 2001;96:2973-7.
17. Liang TJ, Bodenheimer HC Jr, Yankee R, et al: Presence of hepatitis B and C viral genomes in US blood donors as detected by polymerase chain reaction amplification. J Med Virol 1994;42:151-7.
18. Liu CJ, Chen PJ, Shau WY, et al: Clinical aspects and outcomes of volunteer blood donors testing positive for hepatitis-C virus infection in Taiwan: a prospective study. Liver Int 2003;23:148-55.
19. D'Amelio R, Matricardi PM, Biselli R, et al: Changing epidemiology of hepatitis B in Italy: public health implications. Am J Epidemiol 1992;135:1012-8.
20. Treitinger A, Spada C, Ferreira LA, et al: Hepatitis B and hepatitis C prevalence among blood donors and HIV-1 infected patients in Florianopolis-Brazil. Braz J Infect Dis 2000;4:192-6.
21. Shiratori Y, Shiina S, Zhang PY, et al: Does dual infection by hepatitis B and C viruses play an important role in the pathogenesis of hepatocellular carcinoma in Japan? Cancer 1997;80:2060-7.
22. Xess A, Kumar M, Minz S, et al: Prevalence of hepatitis B and hepatitis C virus coinfection in chronic liver disease. Indian J Pathol Microbiol 2001;44:253-5.
23. Kaur S, Rybicki L, Bacon BR, et al: Performance characteristics and results of a large-scale screening program for viral hepatitis and risk factors associated with exposure to viral hepatitis B and C: results of the National Hepatitis Screening Survey. National Hepatitis Surveillance Group. Hepatology 1996;24:979-86.
24. Frank C, Mohamed MK, Strickland GT, et al: The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000;355:887-91.
25. el-Sayed HF, Abaza SM, Mehanna S, et al: The prevalence of hepatitis B and C infections among immigrants to a newly reclaimed area endemic for Schistosoma mansoni in Sinai, Egypt. Acta Trop 1997;68:229-37.
26. Chu CM, Yeh CT, Liaw YF: Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus. Gut 1999;45:613-7.
27. Zarski JP, Bohn B, Bastie A, et al: Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998;28:27-33.
28. Donato F, Boffetta P, Puoti M: A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75:347-54.
29. Benvegnu L, Fottovich G, Noventa F, et al: Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma. A prospective study. Cancer 1994;74:2442-8.
30. Shiratori Y, Shiina S, Zhang PY, et al: Does dual infection by hepatitis B and C viruses play an important role in the pathogenesis of hepatocellular carcinoma in Japan? Cancer 1997;80:2060-7.
31. Sagnelli E, Felaco FM, Filippini P, et al: Multiple hepatitis virus infections in chronic HBsAg carriers in Naples. Arch Virol 1997;142:445-51.
32. Coppola N, Marrocco C, Di Caprio D, et al: Acute hepatitis B and C virus coinfection: a virological and clinical study of 3 cases. Clin Infect Dis 2003;36:528-32.
33. Liaw YF, Tsai SL, Chang JJ, et al: Displacement of hepatitis B virus by hepatitis C virus as the cause of continuing chronic hepatitis. Gastroenterology 1994;106:1048-53.
34. Pontisso P, Ruvoletto MG, Fattovich G, et al: Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology 1993;105:1529-33.
35. Liaw YF, Lin SM, Sheen IS, et al: Acute hepatitis C virus superinfection followed by spontaneous HBeAg seroconversion and HBsAg elimination. Infection 1991;19:250-1.
36. Ohkawa K, Hayashi N, Yuki N, et al: Long-term follow-up of hepatitis B virus and hepatitis C virus replicative levels in chronic hepatitis patients coinfected with both viruses. J Med Virol 1995;46:258-64.
37. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C 2002. Gastroenterology 2002;123:2082-99.
38. Guptan RC, Thakur V, Raina V, et al: Alpha-interferon therapy in chronic hepatitis due to active dual infection with hepatitis B and C viruses. J Gastroenterol Hepatol 1999;14:893-8.
39. Lai MY, Kao JH, Yang PM, et al: Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996;111:1307-12.
40. Davis GL, Esteban-Mur R, Rustgi V, et al: Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1493-9.
41. Reichard O, Norkrans G, Fryden A, et al: Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998;351:83-7.
42. McHutchison JG, Gordon SC, Schiff ER, et al: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
43. Hung CH, Lee CM, Lu SN, et al: Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. J Gastroenterol Hepatol 2005;20:727-32.
44. Chuang WL, Dai CY, Chang WY, et al: Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Antivir Ther 2005;10:125-33.
45. Cacciola I, Pollicino T, Squadrito G, et al: Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999;341:22-6.
46. Kao JH, Chen PJ, Lai MY, et al: Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol 2002;40:4068-71.
47. Fujiwara K, Tanaka Y, Orito E, et al: Lack of association between occult hepatitis B virus DNA viral load and aminotransferase levels in patients with hepatitis C virus-related chronic liver disease. J Gastroenterol Hepatol 2004;19:1343-7.
48. Castillo I, Pardo M, Bartolome J, et al: Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 2004;189:7-14.
49. Pereira BJ, Levey AS: Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997;51:981-99.
50. George SL, Gebhardt J, Klinzman D, et al: Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests. J Acquir Immune Defic Syndr 2002;31:154-62.
51. Tsai SL, Liaw YF, Yeh CT, et al: Cellular immune responses in patients with dual infection of hepatitis B and C viruses: dominant role of hepatitis C virus. Hepatology 1995;21:908-12.
52. Shin CM, Lo SJ, Miyamura T, et al: Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells. J Virol 1993;67:5823-32.
53. Schuttler CG, Fiedler N, Schmidt K, et al: Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C core protein. J Hepatol 2002;37:855-62.
54. Sagnelli E, Pasquale G, Coppola N, et al: Influence of chronic coinfection with hepatitis B and C virus on liver histology. Infection 2004;32:144-8.
55. Yan H, Huang D, Lang Z: Detection of viral markers in liver tissue dually infected with hepatitis B and C viruses by double labeling. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 1999;13:54-6.
56. Hino K, Okita K: Interferon therapy as chemoprevention of hepatocarcinogenesis in patients with chronic hepatitis C. J Antimicrob Chemother 2004;53:19-22.
57. Yalcin K, Degertekin H, Yildiz F, et al: A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin. J Gastroenterol 2003;38:796-800.